Evidence map›Paper›PMID 35049510›Full record

ArticleJMIR medical informatics2022

A Platform and Multisided Market for Translational, Software-Defined Medical Procedures in the Operating Room (OP 4.1): Proof-of-Concept Study.

Magdalena Görtz, Michael Byczkowski, Mathias Rath, Viktoria Schütz, Philipp Reimold, Claudia Gasch, Tobias Simpfendörfer, Keno März, Alexander Seitel, Marco Nolden and 15 more

Open access · goldAbstract read
In one paragraph

Article in JMIR medical informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 1 country.

Magdalena GörtzDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-6195-1609
Michael ByczkowskiSAP SE, Walldorf, Germany.ORCID https://orcid.org/0000-0001-7004-1586
Mathias RathDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-2470-0007
Viktoria SchützDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-2179-747X
Philipp ReimoldDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-7745-5762
Claudia GaschDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-8722-5231
Tobias SimpfendörferDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-2314-3245
Keno MärzGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-3503-1918
Alexander SeitelGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-5919-9646
Marco NoldenGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-9629-0564
Tobias RossGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-7094-4926
Diana Mindroc-FilimonGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-3104-2129
Dominik MichaelGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-6152-7936
Jasmin MetzgerGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-6057-5859
Sinan OnogurGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-8371-760X
Stefanie SpeidelNational Center for Tumor Diseases, Dresden, Germany.ORCID https://orcid.org/0000-0002-4590-1908
Lars MündermannKARL STORZ SE & Co. KG, Tuttlingen, Germany.ORCID https://orcid.org/0000-0002-1228-2477
Johannes FallertKARL STORZ SE & Co. KG, Tuttlingen, Germany.ORCID https://orcid.org/0000-0002-8020-0496
Michael Müllermbits imaging GmbH, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-8269-7504
Magnus von Knebel DoeberitzDepartment of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-0498-6781
Dogu TeberDepartment of Urology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.ORCID https://orcid.org/0000-0002-2586-2550
Peter SeitzSiemens Healthineers AG, Forchheim, Germany.ORCID https://orcid.org/0000-0002-0326-7195
Lena Maier-HeinGerman Cancer Research Center, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-4910-9368
Stefan DuensingSection of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-7840-138X
Markus HohenfellnerDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-3798-2039
German Cancer Research Center · DEHeidelberg University · DEKarl Storz (Germany) · DENational Center for Tumor Diseases · DESiemens Healthineers (Germany) · DEStädtisches Klinikum Karlsruhe · DESystems, Applications & Products in Data Processing (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough digital and data-based technologies are widespread in various industries in the context of Industry 4.0, the use of smart connected devices in health care is still in its infancy. Innovative solutions for the medical environment are affected by difficult access to medical device data and high barriers to market entry because of proprietary systems.

objectiveIn the proof-of-concept project OP 4.1, we show the business viability of connecting and augmenting medical devices and data through software add-ons by giving companies a technical and commercial platform for the development, implementation, distribution, and billing of innovative software solutions.

methodsThe creation of a central platform prototype requires the collaboration of several independent market contenders, including medical users, software developers, medical device manufacturers, and platform providers. A dedicated consortium of clinical and scientific partners as well as industry partners was set up.

resultsWe demonstrate the successful development of the prototype of a user-centric, open, and extensible platform for the intelligent support of processes starting with the operating room. By connecting heterogeneous data sources and medical devices from different manufacturers and making them accessible for software developers and medical users, the cloud-based platform OP 4.1 enables the augmentation of medical devices and procedures through software-based solutions. The platform also allows for the demand-oriented billing of apps and medical devices, thus permitting software-based solutions to fast-track their economic development and become commercially successful.

conclusionsThe technology and business platform OP 4.1 creates a multisided market for the successful development, implementation, distribution, and billing of new software solutions in the operating room and in the health care sector in general. Consequently, software-based medical innovation can be translated into clinical routine quickly, efficiently, and cost-effectively, optimizing the treatment of patients through smartly assisted procedures.

Indexed as

cloud-based platformdataeHealthInternet of Medical ThingsIoTmedical appsmultisided marketperioperative medicinesoftware-defined healthcaretranslational research

Identifiers

PMID35049510
PMCPMC8814925
OpenAlexW3217111626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.